# Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

> **NCT02612428** · PHASE3 · TERMINATED · sponsor: **Vital Therapies, Inc.** · enrollment: 151 (actual)

## Conditions studied

- Acute Alcoholic Hepatitis

## Interventions

- **BIOLOGICAL:** ELAD System
- **OTHER:** Standard of Care (Control)

## Key facts

- **NCT ID:** NCT02612428
- **Lead sponsor:** Vital Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2018-03
- **Final completion:** 2018-09
- **Target enrollment:** 151 (ACTUAL)
- **Why stopped:** VTL-308 failed to meet its primary endpoint, all follow up studies were terminated
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612428, "Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02612428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*